Pacific dengue cases surge, but don't cancel your holiday yet - health expert
On Friday the Cook Islands declared an outbreak of the viral infection, which is spread by mosquitoes, in Rarotonga. Outbreaks have also been declared in Samoa, Fiji and Tonga.
Across the Tasman, there has been a cluster of cases in Townsville and Cairns in Queensland.
Last month a 12-year-old boy died in Auckland after being medically evacuated from Samoa, with severe dengue fever.
Marc Shaw, a medical director at Worldwise Travellers Health Care and a professor in public health and tropical diseases at James Cook University in Townsville, said people travelling to places with dengue fever outbreaks should take precautions to protect themselves against mosquito bites but it was important to be pragmatic.
"Yes, people are getting dengue fever, but considering the number of people that are travelling to these regions, we have to be pragmatic and think about our own circumstances," Dr Shaw said.
"[Just] because you're travelling to the region, it does not mean that you're going to get the disease.
"We should just maintain vigilance and look to protect ourselves in the best ways we can, and having a holiday in these regions should not be avoided."
What should I do to prevent dengue?
Dr Shaw said light-coloured clothes were best as mosquitoes were attracted to dark colours.
"They also tend to be more attracted to perfumes and scents.
"Two hours on either side of dusk and dawn is the time most mosquito bites occur. Mosquitoes also tend to be attracted a lot more to ankles and wrists."
But the best form of protection was a high-strength mosquito repellent containing the active ingredient Diethyl-meta-toluamide or DEET, he said.
"The dengue fever mosquito is quite a vicious mosquito and tends to be around at this particular time of the year. It's good to apply a repellent of around about 40 per cent [strength] and that will give about eight to 10 hours of protection."
Dengue fever was "probably the worst fever anyone could get," he added.
"Unfortunately, it tends to cause a temperature, sweats, fevers, rashes, and it has a condition which is called breakbone fever, where you get the most painful and incredibly painful joints around the elbows. In its most sinister form, it can cause bleeding."
Most people recovered from dengue fever, but those who caught the disease again were much more vulnerable to it, he added.
"Under those circumstances, it is worthwhile discussing with a travel health physician as it is perhaps appropriate that they have a dengue fever vaccine, which is just out."
Dr Shaw said the virus would start to wane in the affected regions from now on as the Pacific region and Queensland head into the drier winter months.
RNZ
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
5 hours ago
- News.com.au
Health Check: On Lamington Day, biotechs serve up their chocolate-dipped quarterly morsels
Today's news is all sweet on trial progress, revenue and cash Amplia to raise capital after runaway share performance Tryptamine starts binge eating 'magic mushie' trial Today is National Lamington Day and biotechs are serving up a solid sponge-like base of news encased in chocolate and coconut – occasionally interspersed with a jam layer. Hold the cream and pink jelly though – it just doesn't work. Like so many drug discoveries, the lamington had serendipitous origins. The story goes that one of Queensland governor Lord Lamington's maids was serving up a yellow sponge, but accidentally dunked it into molten chocolate. Lord Lammo recommended the squares to be rolled into coconut shavings for ease of eating – and the rest is history. As is this non-sequitur. Now onto the biotech news. Lumos glows after last week's mega deal Point-of-care diagnostics house Lumos Diagnostics (ASX:LDX) reports revenue of $12.4 million for the year to June 30, up 12%. June quarter revenue declined 26% to $2.6 million, owing to the end of the US flu season. Lumos reported cash outflows of US$1.7 million for the quarter, taking June 30 cash to US$2 million. Investor interest has focused on last week's mega US distribution deal with Phase Scientific, which could deliver Lumos up to US$317 million ( $487 million) over six years. This pertains to the company's bacterial-versus-viral rapid lateral flow test, Febridx. Lumos has also signed a term sheet for a $5 million loan facility, proffered by shareholders Tenmile Ventures (Andrew Forrest) and Ryder Capital. At its discretion, Lumos can draw down the facility over the next 12 months. Cleo eyes FDA approval for ovarian cancer assay Still on diagnostics, Cleo Diagnostics (ASX:COV) says it aims to submit a US Food & Drug Administration (FDA) marketing approval application for its ovarian cancer assay next year. The company is on track to complete a supportive US trial in the December quarter. Thanks to government grants and tax incentives, Cleo reported cash inflows of $38,000, taking end of quarter cash to $6.46 million. Turning to drug development, genetic disease specialist PYC Therapeutics (ASX:PYC) reports cash outflows of $17.6 million. At quarter's end the company still had cash of $153 million. The company has dosed the first patient in a combined phase 1a/2b trial for polycystic kidney disease. PYC has achieved 'alignment' with the FDA on the structure of a registrational trial for its lead program, the blinding eye disease retinitis pigmentosa type 11. The company believes the regulator will require only a phase II trial. Tryptamine BEDS down eating disorder trial Psychedelic medicines house Tryptamine Therapeutics (ASX:TYP) has started recruiting patients for a world-first binge eating disorder (BED) study. In the open-label trial, 12 patients will be administered intravenously infused psilocybin, combined with psychotherapy. Melbourne's Swinburne University is undertaking the study, with first dosing this quarter and top line results due by the end of the year. BED is the most common eating disorder in the US and second most prevalent in Australia here. The condition can result in depression, anxiety, post-traumatic stress disorder and compulsive behaviour. Amplia passes the hat Meanwhile Amplia (ASX:ATX) shares this morning entered trading halt, ahead of a share placement and share purchase plan. Amplia thus continues the rich tradition of companies leveraging clinical trial results, in this case its stunning data for hard-to-treat pancreatic disease. Amplia has reported 17 'partial response' rates in it Accent trial, in 17 out of 55 advanced disease patients. A confirmed partial response is tumour shrinkage of more than 30%, sustained for two or more months with no new cancerous lesions detected. Amplia is testing AMP-945 (narmafotinib). AMP-945 appears to inhibit the protein FAK, which is overexpressed in pancreatic cancers. Amplia shares have surged 376% in the past 12 months, but investors still value the company at a modest $110 million. As of the end of March, Amplia had cash of $10.8 million. 'Perplexed' Imugene laments soft-as-a-sponge share price Imugene (ASX:IMU) chairman Paul Hopper hopes the company's lamington-soft share price will 'do an Amplia' (our words) and reflect the company's progress with its multiple cancer trials. The company last Monday announced its phase 1b study for an aggressive blood cancer had resulted in two additional 'complete responses' (that is, the tumours disappeared). Imugene is trialing Azer-cel, its allogeneic Car-T drug made from healthy donor T-cells rather than the patient's. Naturally, Imugene announced a $22.5 million and share purchase plan for up to $15 million. On reinstatement, the shares lost 4.5 cents, or 10%, taking the loss over the past year to around 80%. This allows for a one for 34 share consolidation. 'We are very disappointed with the share price performance,' Hopper says. 'We are perplexed why we had such a lukewarm reception to the earlier data at the start of year.' Cashed up for pivotal trial But with the share raising in train, Imugene investors should no longer fear that such a dilutionary event is around the corner. Post raising Imugene should have cash of $64 million, with management costing a 60-80 patient pivotal trial at $30-40 million. If approved, Azer-cel would be the first commercial allogenic Car-T treatment, enabling mass produced, off-the-shelf therapies. 'We are in active discussions with partners on the strategy for developing the drug and getting it approved,' Hopper says. Shares settle in orbit after last week's Meso-blast off Mesoblast (ASX:MSB) shares have taken a breather after Friday's 35% surge on the back of initial US sales of its first US-approved stem cell product. The company reported unaudited June quarter revenue of US$13.2 million ($20.3 million) for Ryoncil, its treatment for childhood graft-versus-host disease. The FDA approved Ryoncil in December last year. Mesoblast founder and CEO Prof Silviu Itescu points to higher sales in the current quarter, given US Centres for Medicare and Medicaid Services coverage became effective on July 1. The company has signed up more than 25 transplant centres and hopes to enlist all 45 priority centres by October. Bell Potter analyst John Hester says the sales were in line with the firm's expectations. 'The figure is inclusive of sales to the distributor, nevertheless it represents a reasonable proxy for hospital demand.' The firm values Mesoblast at $3.50 a share, implying 55% of upside.
News.com.au
9 hours ago
- News.com.au
UK battles anti-vax misinformation after child's death
A child's death from measles has sparked urgent calls from British public health officials to get children vaccinated, as the UK faces an onslaught of misinformation on social media, much of it from the United States. Measles is a highly infectious disease that can cause serious complications. It is preventable through double MMR (measles, mumps and rubella) jabs in early childhood. Health Secretary Wes Streeting on July 14 confirmed to parliament that a child had died in the UK of measles. No details have been released, but The Sunday Times and Liverpool Echo newspapers reported the child had been severely ill with measles and other serious health problems in Alder Hey hospital in the northwestern city. Anti-vaxxers quickly posted unconfirmed claims about the death on social media. One British influencer, Ellie Grey, who has more than 200,000 followers on Instagram, posted a video denying the child died from measles. "Measles isn't this deadly disease... it's not dangerous," she said. Grey criticised Alder Hey for posting a video "really, really pushing and manipulating parents into getting the MMR vaccine". Her video was reposted by another British influencer, Kate Shemirani, a struck-off ex-nurse who posts health conspiracy theories. "No vaccine has ever been proven safe and no vaccine has ever been proven effective," Shemirani claimed falsely. Liverpool's public health chief Matthew Ashton attacked those "spreading misinformation and disinformation about childhood immunisations" in the Echo newspaper, saying "they need to take a very long, hard look at themselves." "For those of you that don't know, measles is a really nasty virus," he said in a video, adding that the jab is a way of "protecting yourself and your loved ones". Alder Hey said it has treated 17 children with measles since June. It posted a video in which a paediatric infectious diseases consultant, Andrew McArdle, addresses measles "myths", including that the MMR jab causes autism. This false claim comes from a debunked 1998 study by a British doctor, Andrew Wakefield, who was later struck off. But it sparked an international slump in vaccinations. - 'Lingering questions' - Benjamin Kasstan-Dabush, a medical anthropologist at the London School of Hygiene and Tropical Medicine, told AFP there are still "lingering questions around the Wakefield era". He talked to parents who had delayed vaccinating their children, finding reasons included life events and difficulty getting health appointments, but also misinformation. "We're obviously talking about a different generation of parents, who might be engaging with that Wakefield legacy through social media, through the internet, and of course through Kennedy," he said. US President Donald Trump appointed Robert F. Kennedy Jr as health secretary despite his promotion of anti-vaccine conspiracy theories. Kennedy fired all 17 experts on a key vaccine advisory panel and appointed a scientist who warned against Covid jabs. In the United States, "misinformation is being produced in the highest echelons of the Trump administration", which "circulates across the internet", Kasstan-Dabush said. In a sign of how narratives spread, a Telegram group airing conspiracies called Liverpool TPR, which has around 2,000 members, regularly posts links to anti-vaccine group Children's Health Defense once chaired by Kennedy. In the past few weeks the UK Health Security Agency has amplified its social media coverage on vaccinations, a spokesman said. In a video in response to the reported death, Vanessa Saliba, a consultant epidemiologist, explained the MMR jab protects others, including those "receiving treatment like chemotherapy that can weaken or wipe out their immunity". Take-up of the MMR jab needs to be 95 percent for herd immunity, according to the World Health Organisation. The UK has never hit this target. In Liverpool, uptake for both doses is only around 74 percent and below 50 percent in some areas, according to Ashton, while the UK rate is 84 percent. After Wakefield's autism claims, confirmed measles cases topped 2,000 in England and Wales in 2012 before dropping. But last year, cases soared again. The same trend is happening in other countries. Europe last year reported the highest number of cases in over 25 years; the United States has recorded its worst measles epidemic in over 30 years. Canada, which officially eradicated measles in 1998, has registered more than 3,500 cases this year.
ABC News
16 hours ago
- ABC News
Federal government will face pressure to add dental to Medicare, amid 'overwhelming' wait times
Queensland pensioner Don Batty has always looked after his teeth, but age has taken its toll. These days, the former NSW Police officer finds it hard to look in the mirror. "I'm 80 years old now and my teeth have started to disintegrate," he told the ABC. The Toowoomba resident is missing multiple molars, which makes it hard to chew food. His dental issues affect his diet, speech and confidence. He has been living like this for nearly two years because he cannot afford to visit a private dentist. "It would be totally impossible. "There is no way I can save enough money to spend the thousands that are required to go to a private dentist." Mr Batty is among 140,000 Queenslanders waiting for non-urgent public dental care. More than 10,000 patients have been added to the queue in the past year. "I've been waiting now for about 21 months," Mr Batty said. "We've got a very, very good dental service, but it's overwhelmed. There's no way they can deal with the number of people in this city and surrounding towns with the resources they've got." Data obtained by the ABC shows patients in every state and territory can expect to wait months, if not years, for non-urgent public dental care. Around one-third of Australians are eligible for the free or low-cost public dental services, which are delivered by state and territory governments with some funding from the Commonwealth. There are variations in how states and territories record and report their data, but the figures are similar. Queensland Health says it is "desirable" to provide a patient with general dental care within two years. In New South Wales, the "maximum recommended waiting time" for patients seeking non-urgent routine care is around 18 months. The Victorian Health Department said the average wait for the state's non-urgent public dental services was 12.4 months. The most recent data available shows the longest wait times were in Tasmania and the Northern Territory. In Tasmania, 50 per cent of patients removed from the waitlist in the past 12 months had been there for more than 2.5 years. In the NT, the median wait time for a first appointment from 2023 to 2024 was also around 2.5 years, according to data compiled by the Australian Institute of Health and Welfare (AIHW). The AIHW also found about 10 per cent of patients in Tasmania and the NT waited nearly five years for their first appointment. The shortest waiting times were in Western Australia, where last year patients received non-urgent care after an average of 5.4 months. In South Australia, the average wait was seven months. No average or median wait list data was available for the ACT. Each state and territory government told the ABC that patients in priority groups or those requiring urgent care did not have to wait for treatment. Australian Dental Association president Chris Sanzaro said the issue was adding pressure to other parts of the health system. "Around Australia there's nearly 90,000 potentially preventable hospitalisations each year due to dental disease. "There's a lot of links between poor dental health and overall health. The one link we know is very strong is between diabetes and poor dental health." Grattan Institute health program director Peter Breadon said the public dental system was underfunded and "overwhelmed". "Of all the funding that goes into dental care in Australia, about 60 per cent comes out of the pockets of patients, in the form of fees," he said. "To put that in perspective … it's nine times the share that comes from patients when you see a GP." As the new federal parliament prepares to begin its work this week, the Greens are vowing to ramp up pressure on the government to add dental to Medicare. Despite being nearly wiped out in the lower house at the federal election, the minor party is returning to Canberra with the sole balance of power in the Senate. This means the government will rely entirely on its support to pass legislation when the Coalition is not on board. Greens Health spokesperson Jordon Steele-John said he would be "pulling every lever as an MP" to get dental added to Medicare. "We are excited and energised as a party to get to work," Mr Steele-John said. When asked if the Greens would refuse to back bills if the government didn't agree to add dental to Medicare, he did not rule it out. But he added his "starting point" would be to work with people across parliament to create a consensus on the issue. Mr Steele-John described the beginning of the new parliamentary term as "an opportunity to strike a new tone". "To signal clearly you are willing and excited to work with people of goodwill to get something done for the community," he said. The Greens have previously indicated they will take a less hardline approach in the upcoming parliament, after losing three lower house MPs at the federal election, including then-leader Adam Bandt. In the previous term, the party used its senate numbers to block a bill designed to ease the housing crisis, as it pushed for more rights for renters. New leader Larissa Waters said the Greens wanted to be "firm but constructive" in the new term. The minor party campaigned heavily on the issue of adding dental to Medicare ahead of the election, and was encouraged by comments previously made by Health Minister Mark Butler. Mr Butler told the ABC in March: "Our party would love to bring dental into Medicare at some stage. We've got that as part of our platform commitment." When pressed over the possible timing this week, Mr Butler said in a statement the government's immediate focus was on strengthening Medicare and rebuilding general practice. "I can't say to people that in the short term there's going to be any change to dental," he said. "But I do recognise in the longer term there's a lot of ambition for dental to be covered by Medicare." The federal government has previously indicated it cannot yet add dental to Medicare due to the cost. Policy experts and dentists argue dental services could be added to Medicare in stages, to keep costs down. The Australian Dental Association claims the first step should be a Medicare-funded dental scheme for seniors. "It would be somewhere between $1.1 billion and $1.4 billion a year," Dr Sanzaro said. "A means-tested scheme, with a capped amount available to every individual every couple of years." The Grattan Institute estimates it would cost $8 billion a year to gradually add dental services into the Medicare scheme over a decade. "Obviously you can't just turn on a switch and put that much money into the system," Mr Breadon said. Some children are already eligible for free or low-cost dental through the Child Dental Benefits Schedule under Medicare. Around 3.5 million children have received treatment through the scheme since it started in 2014.
